Molecular tests can’t detect the complex oncogenic activity driving many cancers. CELsignia, our 3rd generation cellular analysis platform, unravels the complex oncogenic activity molecular tests cannot detect. This enables us to discover previously undetectable cancer drivers and new therapeutic options for cancer patients.
With the unique tumor insights CELsignia generates, we can identify new applications for targeted therapies and develop potential first-in-class drugs.